SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice

Published:2019-03-16 Issue:5 Volume:8 Page:e1577127
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ajina Reham¹,Zamalin Danielle²,Zuo Annie¹,Moussa Maha³,Catalfamo Marta³,Jablonski Sandra A.¹,Weiner Louis M.¹

Affiliation:

1. Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

2. Department of Human Science, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA

3. Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, USA

Funder

National Cancer Institute

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1577127

Reference22 articles.

1. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes

2. A multiplex CRISPR/Cas9 platform for fast and efficient editing of multiple genes in Arabidopsis

3. Development and Applications of CRISPR-Cas9 for Genome Engineering

4. CRISPR interference (CRISPRi) for sequence-specific control of gene expression

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice;Cancer Research Communications;2024-04-09

2. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors;Nature Communications;2024-01-02

3. Hydroxyphenylpyruvate Dioxygenase Is a Metabolic Immune Checkpoint for UTX-deficient Colorectal Cancer;Gastroenterology;2023-06

4. An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer;Journal for ImmunoTherapy of Cancer;2023-03

5. Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation;Frontiers in Bioengineering and Biotechnology;2023-02-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3